These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 4317437)

  • 1. [Influence of treatment in the cardiovascular reactivity of the hypertensive patient].
    Garcia R; Perez-Olea J; Sanchez J; Quevedo M
    Rev Med Chil; 1968 Jul; 96(7):451-6. PubMed ID: 4317437
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of antihypertensive treatment on vascular remodeling in essential hypertensive patients.
    Schiffrin EL; Deng LY; Larochelle P
    J Cardiovasc Pharmacol; 1994; 24 Suppl 3():S51-6. PubMed ID: 7700067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Emergency prehospital care for uncomplicated hypertensive crisis].
    El'kis IS; Borisova VA; Ovasapian IuA; Sidorov AM
    Ter Arkh; 2006; 78(1):20-3. PubMed ID: 16512440
    [No Abstract]   [Full Text] [Related]  

  • 4. Serial hemodynamic measurements allow better blood pressure control than clinical judgment in those with refractory hypertension.
    Basile J
    J Clin Hypertens (Greenwich); 2002; 4(6):434-5. PubMed ID: 12461310
    [No Abstract]   [Full Text] [Related]  

  • 5. Cerebral blood flow autoregulation in hypertension and effects of antihypertensive drugs.
    Barry DI; Lassen NA
    J Hypertens Suppl; 1984 Dec; 2(3):S519-26. PubMed ID: 6400382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].
    Qiu YG; Yao XY; Tao QM; Zheng P; Chen JZ; Zhu JH; Zhang FR; Zheng LR; Zhao LL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone antagonist therapy in resistant hypertension.
    Zannad F
    J Hypertens; 2007 Apr; 25(4):747-50. PubMed ID: 17351364
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.
    Brooks DP; Ruffolo RR
    J Hypertens Suppl; 1999 Jun; 17(2):S27-32. PubMed ID: 10465064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Vascular reactivity of hypertensive patients treated with pargyline-methylchlorothiazide].
    Vukusic A; Garcia R; Perez-Olea J
    Rev Med Chil; 1968 Jan; 96(1):27-30. PubMed ID: 5732740
    [No Abstract]   [Full Text] [Related]  

  • 11. Measures of total stress-induced blood pressure responses are associated with vascular damage.
    Nazzaro P; Seccia T; Vulpis V; Schirosi G; Serio G; Battista L; Pirrelli A
    Am J Hypertens; 2005 Sep; 18(9 Pt 1):1226-32. PubMed ID: 16182114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment.
    Schiffrin EL
    Am J Hypertens; 2004 Dec; 17(12 Pt 1):1192-200. PubMed ID: 15607629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of resistance artery stiffness by treatment with the AT(1)-receptor antagonist losartan in essential hypertension.
    Park JB; Intengan HD; Schiffrin EL
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):40-5. PubMed ID: 11967798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hypertension and hemorheology].
    Klein W; Eber B; Dusleag J; Gasser R; Fruhwald FM; Schumacher M; Zweiker R; Stoschitzky K
    Wien Med Wochenschr; 1995; 145(15-16):355-7. PubMed ID: 7502514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Class of antihypertensive drugs, blood pressure status, and risk of cardiovascular disease in hypertensive patients: a case-control study in Japan.
    Kono S; Kushiro T; Hirata Y; Hamada C; Takahashi A; Yoshida Y
    Hypertens Res; 2005 Oct; 28(10):811-7. PubMed ID: 16471175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in the modification of cardiovascular responses by sympathetic inhibitory drugs.
    Prichard BN
    Proc R Soc Med; 1969 Jan; 62(1):84-91. PubMed ID: 5763482
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypertension and microvascular remodelling.
    Feihl F; Liaudet L; Levy BI; Waeber B
    Cardiovasc Res; 2008 May; 78(2):274-85. PubMed ID: 18250145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher small arterial elasticity in hypertensive patients treated with angiotensin II receptor blockers.
    Takeuchi K; Ideishi M; Tashiro T; Morishige N; Yamada T; Saku K; Urata H
    Hypertens Res; 2005 Aug; 28(8):639-44. PubMed ID: 16392767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New, in Austria registered specialty drugs. Normoxin (moxonidine)].
    Kögler H; Raneburger J
    Wien Klin Wochenschr; 1993; 105(3):94-6. PubMed ID: 8447129
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.